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Abstract: In many forms of erectile dysfunction (ED), cardiovascular risk factors, in particular
arterial hypertension, seem to be extremely common. While causes for ED are related to a broad
spectrum of diseases, a generalized vascular process seems to be the underlying mechanism in
many patients, which in a large portion of clinical cases involves endothelial dysfunction, ie,
inadequate vasodilation in response to endothelium-dependent stimuli, both in the systemic
vasculature and the penile arteries. Due to this close association of cardiovascular disease and
ED, patients with ED should be evaluated as to whether they may suffer from cardiovascular
risk factors including hypertension, cardiovascular disease or silent myocardial ischemia. On
the other hand, cardiovascular patients, seeking treatment of ED, must be evaluated in order to
decide whether treatment of ED or sexual activity can be recommended without significantly
increased cardiac risk. The guideline from the first and second Princeton Consensus Conference
may be applied in this context. While consequent treatment of cardiovascular risk factors should
be accomplished in these patients, many antihypertensive drugs may worsen sexual function as
a drug specific side-effect. Importantly, effective treatment for arterial hypertension should not
be discontinued as hypertension itself may contribute to altered sexual functioning; to the
contrary, alternative antihypertensive regimes should be administered with individually tailored
drug regimes with minimal side-effects on sexual function. When phosphodiesterase-5 inhibitors,
such as sildenafil, tadalafil and vardenafil, are prescribed to hypertensive patients on
antihypertensive drugs, these combinations of antihypertensive drugs and phosphodiesterase 5
are usually well tolerated, provided there is a baseline blood pressure of at least 90/60 mmHg.
However, there are two exceptions: nitric oxide donors and α-adrenoceptor blockers. Any drug
serving as a nitric oxide donor (nitrates) is absolutely contraindicated in combination with
phosphodiesterase 5 inhibitors, due to significant, potentially life threatening hypotension.
Also, α-adrenoceptor blockers, such as doxazosin, terazosin and tamsulosin, should only be
combined with phosphodiesterase 5 inhibitors with special caution and close monitoring of
blood pressure.
Keywords: Sexual function, erectile dysfunction, hypertension, antihypertensive therapy,
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Introduction
Arterial hypertension is a systemic disorder characterized by altered regulation of
cardiovascular hemodynamics including arterial vascular resistance and cardiac index
leading in effect to increase in arterial blood pressure. Whether the hypertension is of
the essential type, without obvious underlying disease, or secondary arterial
hypertension due to primary causes, such as renal, vascular, metabolic, endocrine, or
other disorders, chronically elevated blood pressure is regarded as an established risk
factor for the development of cardiovascular disease, such as stroke, chronic ischemic
heart disease, myocardial infarction and heart failure. Therefore, arterial hypertension
should be the target of vigorous treatment attempts both in primary and secondary
preventive medicine (MacMahon et al 1990).Vascular Health and Risk Management 2006:2(4) 448
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At first sight, erectile dysfunction (ED) seems to be a field
quite different from cardiovascular medicine. However, a closer
look demonstrates that it is strongly associated with arterial
hypertension and also several other cardiovascular risk
factors. Many cases of ED are characterized as “vascular”,
referring to their strong statistical association with
cardiovascular risk factors and cardiovascular events (Virag
et al 1995; Schwarz et al 2005). Among others, hypertension
is a cardiovascular risk factor which is significantly associated
with ED (Bansal 1988; Kloner 2000). In the Massachusetts
Male Aging Study the annual incidence of ED in a population
of 40–69 year old men amounted to 26 new cases per 1000
men. While the incidence in absolute numbers progressively
increased with age, hypertension and also diabetes mellitus
and heart disease were significantly associated with ED in
every age group (Feldman et al 1994; Johannes et al 2000). A
systematic evaluation of atherogenic risk factors among men
with ED reported a prevalence of 44% for hypertension, 79%
for obesity, 74% for elevated low-density lipoprotein
cholesterol (above 120 mg/dL), 23% for diabetes mellitus,
and 16% for smoking (Walzak et al 2002). As recently
demonstrated, this strong association between the presence
of ED and cardiovascular risk factors results in a significantly
increased incidence of cardiovascular events among patients
with ED (Blumentals et al 2004). A retrospective analysis of
the placebo group from the Prostate Cancer Prevention Trial
estimated an 11% 5-year risk of cardiovascular events in
patients suffering from ED, which in current terminology of
preventive medicine means that ED can be regarded as a
“coronary risk equivalent” (Thompson et al 2005).
The following paragraphs will discuss some basic aspects
of this interrelation between hypertension and ED with
respect to similarities in pathophysiology and potential
interaction of medical treatment options of the two diseases.
Erectile dysfunction: warning for
cardiovascular risk factors and
cardiovascular disease
Endothelial dysfunction: common
denominator of atherogenic risk
factors and erectile dysfunction
Table 1 presents a list of potential causes and factors associated
with ED, which should be considered in the patient’s work-up.
Some of them are related to underlying urological, psychosocial
or endocrine disorders. However, it is clear that factors associated
with the cardiovascular system appear to play a predominant
role (Table 1).
The endothelium, ie, the inner layer of cells that line the
vascular network, contributes significantly to vasomotor
regulation, via release of nitric oxide (NO), which is a potent
vasodilator. Endothelial dysfunction is defined as a reduced
vasodilation or even paradoxic vasoconstriction in response to
endothelium-dependent vasodilatory stimuli. In many
circumstances endothelial dysfunction precedes morphological
changes of the vessel wall or the formation of atherosclerotic
plaques. In particular, hypertension might be associated with
endothelial dysfunction as shear stress within the vessel wall,
hypertension, and associated conditions seem to affect
endothelial function significantly (Ludmer et al 1986; Nabel
et al 1988; Taddei et al 1993; Nava et al 1995; Cardillo et al 1998).
In many patients with ED, inadequate release of NO from
nerve endings and endothelial cells or altered response of penile
Table 1 Risk factors, conditions, and diseases associated with
erectile dysfunction
Risk factor associated with atherosclerosis:
• Smoking
• Diabetes mellitus
• Hypertension
• low levels of HDL cholesterol/high levels of LDL cholesterol/
high level of total cholesterol
• sedentary lifestyle
• family history of atherosclerosis
• obesity
Neurological factors
• neuropathy (diabetic, etc)
• spinal cord injury, cerebrovascular insult, multiple sclerosis,
nerve damage due to prostate surgery etc.
Medical diseases
• renal failure,
• dialysis,
• abnormal liver function,
• endocrine disorders (hypogonadism, hyperprolactenemia,
hypo- and hyperthyroidism),
• sickle cell anemia
Drugs
antihypertensives, thiazide diuretics, spironolactone, digoxin,
antidepressants, β-blockers, centrally acting antihypertensives,
phenothiazines, carbamazepin, phenytoin, risperidone, fibrates,
statins, Histamine-2-receptor antagonists, allopurinol,
indomethacin, tranquilizer, disulfiram, levodopa,
chemotherapeutics, etc.
alcohol, others
Others
Peyroni’s disease, priapism, trauma
Psychosocial causes
depression, anxiety disorder, problems or changes in
relationship
Compiled according to Brock et al. 1993; NIH Consensus Development Panel on
Impotence 1993; Benet et al. 1995; Greiner et al. 1996; Keene et al. 1999; Kloner
et al. 1999; Kloner et al. 2002; Levine 2000; McVary et al. 2001; Nusbaum et al. 2002;
Moulik et al. 2003; Nicolosi et al. 2003; Nurnberg et al. 2003, and Roth et al. 2003.Vascular Health and Risk Management 2006:2(4) 449
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vascular smooth muscle cells to NO appears to be an important
step in the pathophysiology of ED (Billups 2004). ED, in this
context, can be regarded as one manifestation of a generalized
process of vascular deterioration. A recent study examined
endothelium-dependent and endothelium-independent
vasodilation of the brachial artery in men with ED, but without
other clinically overt cardiovascular disease (Kaiser et al 2004).
Vasodilation of the brachial artery by both mechanisms was
significantly compromised in the group suffering from ED, which
illustrates that vascular alterations involved in ED are a
generalized process.
Phosphodiesterase 5 inhibitors, namely sildenafil, vardenafil,
and tadalafil, which are currently considered to be the most
effective medical treatment options for ED, intervene in this
pathway of vascular dysfunction (Reffelmann et al 2003): When
NO stimulation increases activity of the enzyme guanylate
cyclase, intracellular cGMP levels are increased. This mechanism
might be further amplified and prolonged in duration by
inhibition of the enzyme phosphodiesterase 5, which is
responsible for the breakdown of cGMP. Thereby, inadequate
vasodilation of the penile arteries in ED as a result of insufficient
release of NO can be compensated for by phosphodiesterase 5
inhibition (Gresser and Gleiter 2002; Gross 2005; Reffelmann
and Kloner 2005a, b).
Cardiovascular work-up for the patient
presenting with erectile dysfunction
Patients without obvious causes for ED, such as anatomical
disorders, neurological disease or endocrine causes should
be evaluated for cardiovascular risk factors, arterial
hypertension, and vascular or arterial disease (Kloner and
Jarow 1999; Kim et al 2001; Sairam et al 2001; Solomon et al
2003). The relatively high probability of detecting potentially
serious diseases warrants further investigations (Gazzaruso
et al 2004; Reffelmann and Kloner 2005a, b).
In addition, the strong association between cardiovascular
risk factors and ED should be brought to the patient’s
attention, as this, in some patients, might be a more convincing
motivation to modify these risk factors, change lifestyle,
effectively treat hypertension, quit smoking, and others, than
the sometimes more abstract statistical association between
cardiovascular disease and risk factors.
In general, we propose the following medical work-up for
a patient presenting with ED with reasonable modification
depending on the individual condition. The patient needs to
supply a detailed medical history including sexual and
psychosocial history along with a complete list of current and
previous medication. A cardiovascular examination including
peripheral pulses, signs of peripheral ischemia, and others is
necessary. To assess the individual risk for cardiovascular
diseases, repeated measurement of blood pressure, a fasting
blood glucose level, analysis of cholesterol (total, low-density
lipoproteins and high-density lipoproteins), body-mass index
(according to weight and height), assessment of lifestyle, actual
level of physical activity, and potential genetic predisposition
should be obtained. A resting electrocardiogram should also
be documented. If a patient has three or more atherogenic
risk factors an exercise electrocardiogram should be
considered as per the Princeton Consensus Panel. In some
high risk patients a Doppler-sonographic examination of the
carotid arteries and lower extremity arteries might also be
included into the work-up.
Patients with diabetes suffering from ED are at special risk
for silent cardiovascular disease (Gazzaruso et al 2004).
Therefore, some authors recommend an exercise test for every
diabetic patient presenting with ED, as a significant number
of patients with silent ischemic heart disease will be detected
(Stern 2005).
 If the results suggest an increased risk for cardiovascular
disease, a referral to a cardiologist is reasonable for detailed
diagnostic testing and initiation of therapy. Importantly, the
cardiac situation should be carefully clarified before initiation
of medical treatment, as phosphodiesterase 5 inhibitors must
not be used in certain cardiovascular conditions or at least
require special precaution (see below). In addition, detailed
recommendations for cardiovascular patients, concerned
about a potential risk of sexual intercourse in the light of
their underlying cardiovascular condition, are available both
for further diagnostic work up and therapeutic interventions
according to the first and second Princeton Consensus
Conference (DeBusk 2000; Kostis et al 2005). Patients are
categorized as low-risk, high risk, or, if stabilization or further
diagnostics are necessary, as indeterminate or intermediate
risk (Table 2). In the high-risk group, sexual activity should
be deferred until a patient’s cardiac condition has been
stabilized by medical treatment, revascularization procedures
or by simply waiting until stabilization has occurred. In the
intermediate group, further work-up is required, which in many
circumstances needs referral to a cardiologist.
Patients whose blood pressure is well controlled with one
or more antihypertensive drugs are categorized as belonging
to the “low-risk group”, meaning that sexual activity and also
treatment for ED could be safely recommended. However,
patients with poorly controlled hypertension, or hypertensionVascular Health and Risk Management 2006:2(4) 450
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before initiation of adequate treatment or malignant
hypertension are categorized as “high-risk” for cardiac or
vascular events, especially also for stroke (Kostis et al 2005).
As a consequence these patients first require medical treatment
of hypertension and also a diagnostic work-up of
accompanying medical disorders.
Sex: a risk for a cardiovascular
patient?
Among patients and doctors there is substantial uncertainty
as to whether sexual activity in different cardiovascular
conditions and stages of heart disease can be safely
recommended. A cardiovascular patient asking for treatment
options for ED, who might have not been sexually active for a
certain period of time, needs a realistic, individual estimate of
a potential risk of a cardiac event related to sexual intercourse
preferentially based on recommendations of the (first and
second) Princeton Consensus Conference (DeBusk 2000;
Kostis et al 2005).
Statistically, available data suggest that the risk of myocardial
infarction and sudden cardiac death during sexual intercourse,
the so-called coition-induced death, is very low. Fewer than 1%
of myocardial infarctions occur during sexual intercourse, and
only about 0.6% of sudden cardiac deaths may be related to
sexual activity (Muller et al 1996; DeBusk 2000; Jackson 2000;
Ueno 2000). Nonetheless, sexual activity, even if associated
with a very low absolute risk, is an established trigger of
myocardial infarction (DeBusk 2000). A 50-year-old man in the
US is considered to have a baseline risk of myocardial infarction
of 1.00% per year. This risk increases to 1.01% as a consequence
of sexual activity. For patients with prior myocardial infarction,
the risk may increase to 1.10%. Using cross-over statistics, Muller
et al (1996) estimated the relative risk of myocardial infarction
occurring during and within a 2-hour period after sexual
intercourse as being 2.5 in comparison with non-sexual activities.
Importantly, the relative risk in patients with known cardiac
disease was 2.1. Interestingly, regular physical activity and
cardiovascular risk factor modification might further reduce the
risk (Stein 1977; DeBusk 1996). Patients with ischemic heart
disease who have undergone successful revascularization
(percutaneous transluminal angioplasty or coronary artery bypass
surgery) are not at increased risk of myocardial infarction during
sexual intercourse compared with the general population
(Jackson 1999).
In general, physical activity is regarded as a trigger of cardiac
events in susceptible patients (Muller et al 1997). With respect
to the cardiovascular system, sexual intercourse can be regarded
as physical activity resulting in increased blood pressure and
heart rate, which is not decisively different from other physical
exercise in daily life.
While energy expenditures during sexual intercourse may
vary depending on many individual factors, estimates were
obtained in a laboratory setting by Bohlen et al (1984) using
the metabolic equivalent of energy expenditure (MET) in
the resting state (equal to 3.5 mL/kg/min oxygen
consumption) as a quantitative parameter. Healthy males
attained 2.5–3.3 METs during sexual stimulation and orgasm
with some variability (2.0–5.4 METs). For comparison with
daily life activities, one might say that 3 METs equals briskly
climbing two flights of stairs, and 5 METs may be compared
with digging in the garden. Peak heart rate during sexual
intercourse ranged between 110 and 127 beats/minutes in
Table 2 Three risk groups of patients with cardiovascular
disease according to the “Second Princeton Consensus Panel”
(Kostis 2005; see also DeBusk 2000)
1. Low risk group
Patients with
• Two or less atherogenic risk factors, asymtomatic
• Medically controlled hypertension with ≥1 antihypertensive
drug
• mild, stable angina (consider exercise test in some cases)
• after successful coronary revascularization (without remaining
ischemia)
• after uncomplicated myocardial infarction (>6–8 weeks)
• mild valvular disease
• Left ventricular dysfunction: New York Heart Association I
2. Intermediate or indetermined risk group
Patients with
• Three or more atherogenic risk factors, asymptomatic
• moderate, stable angina
• myocardial infarction (2–6 weeks after the acute event)
• congestive heart failure: New York Heart Association II
• non-cardiac sequelae of atherosclerotic disease (stroke,
transient ischemic attack, peripheral vascular disease)
3. High risk group
Patients with
• unstable angina /refractory angina
• untreated, poorly controlled, accelerated, or malignant
hypertension
• congestive heart failure (New York Heart Association III–IV)
• myocardial infarction (within the last 2 weeks)
• recent stroke
• moderate to severe valvular heart disease, particularly aortic
stenosis or hypertrophic obstructive cardiomyopathy
• high risk arrhythmiaVascular Health and Risk Management 2006:2(4) 451
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these individuals (Bohlen 1984). In these investigations, heart
rate rarely increased to more than 130/min and systolic blood
pressure rarely exceeded 170 mmHg in healthy individuals
(Bohlen et al 1984; DeBusk 2000).
A possible conclusion derived from these measurements
might be that a patient, who is able to achieve 5–6 METs on
exercise testing without signs of ischemia, major arrhythmia
or inadequate increase of blood pressure, may not be at excess
risk for a cardiac event during sexual activity. In addition,
effort-induced triggering of myocardial infarction is, in
general, believed to be reduced by revascularization and
optimized medical treatment using aspirin, β-blockers and
lipid-lowering strategies (Jackson 1997, 2000).
Antihypertensive interventions:
cause or cure of erectile
dysfunction?
The close association between hypertension and other
cardiovascular risk factors and the presence of ED respectively
and also the similarities in pathophysiology might suggest
that adequate treatment of hypertension and other risk factors
could favorably influence the severity or progression of ED
or even result in reversal of symptoms. To the contrary,
however, many antihypertensive drugs might even worsen
sexual function as a drug specific side-effect, which could
significantly decrease patient adherence to anti-hypertensive
treatment, further increasing risk of cardiovascular morbidity.
This might be true, in particular, if the question of sexual
health is not openly addressed between the patient and
the clinician.
Epidemiological data suggest that cessation of tobacco
use can in part reverse ED (McVary et al 2001). For diabetes
mellitus, better glycemic control, measured as lower levels
of glycosylated hemoglobin is associated with less severity
and lower incidence of ED (Romeo et al 2000). But for
hypertension, such clear data is not consistently available:
Possibly two confounding factors, drug-specific side effects
and beneficial effects of effective blood pressure control may
make it difficult or impossible to tell whether treatment of
hypertension can attenuate ED.
In general, one might consider lifestyle changes and/or
medical treatment as a potential therapeutic strategy. It is
quite well established that lifestyle changes associated with
reduced arterial blood pressure, such as initiation of physical
activity and weight loss, favorably influence sexual function.
These lifestyle changes seem to be most effective at younger
age compared with older patients (Derby et al 2000).
There are experimental animal investigations, suggesting
that medical treatment of hypertension may have the potential
to reduce the incidence of ED (Hale et al 2001). However,
most medical antihypertensive interventions, such as
thiazides, β-blocking agents etc, were reported to potentially
worsen sexual function.
An exception to this rule is the experience with angiotensin
II receptor type-1 blockers (Llisterri et al 2001), which seem to
slightly improve sexual function along with effective blood
pressure control. For losartan and valsartan, clinical studies
demonstrated a reduction in the incidence of ED and a slight,
but consistent improvement in common parameters of erectile
function (Ferrario et al 2002; Dusing 2003). Moreover, animal
studies supported the concept of improved sexual function
along with effective blood pressure control under the influence
of losartan (Tobbli et al 2004; Park et al 2005).
When choosing the appropriate antihypertensive regime,
one should also bear in mind that, for example, thiazide
diuretics are reported to have a higher incidence of ED than
β-blocking agents, the most commonly mentioned drugs in
this context (Table 3). In addition, a simple weight loss diet
may reverse sexual dysfunction induced by thiazide
diuretics (Langford et al 1989). Loop diuretics might be a
better choice than thiazides and angiotensin II receptor
type-1 blocker may have some benefit compared with
angiotensin converting enzyme inhibitors (Carvajal et al
1995). Calcium channel antagonists do not appear to have
a high incidence of ED albeit in some cases prolactin levels
increase which could interfere with sexual function. In
Table 3 a summary of some alternatives is shown when
choosing the appropriate drug regime in cardiovascular,
particularly hypertensive patients.
Interaction between treatment
of erectile dysfunction and
treatment of hypertension
Phosphodiesterase 5 inhibitors and
arterial blood pressure
As mentioned above, phosphodiesterase 5 inhibitors, such as
sildenafil, vardenafil and tadalafil, inhibit the breakdown of
cGMP in tissues with significant phosphodiesterase 5 activity,
eg, the penile vasculature, resulting in enhanced erections.
Phosphodiesterase 5 is also expressed in systemic vascular
smooth muscle cells including the arterial, venous, pulmonary
and coronary network; bronchial smooth muscle cells;
platelets and the central nervous system (Wallis et al 1999).Vascular Health and Risk Management 2006:2(4) 452
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Looking at the mechanism of action, one could imagine that
administration of phosphodiesterase 5 inhibitors, intended to
treat ED, could also alter vascular hemodynamics, lower blood
pressure or affect the coronary circulation. This might be of
special interest in hypertensive patients or patients on various
antihypertensive drugs. However, in general, blood pressure
lowering effects of the three phosphodiesterase 5 inhibitors
do not appear to be a major problem. Oral administration of
sildenafil reduced systolic and diastolic blood pressure by 7–
10 mmHg in a non-dose dependent manner (Zusman et al
1999) without any evidence of significant reflex tachycardia.
Similarly, effects of sildenafil on blood pressure in hypertensive
patients on multiple antihypertensive drugs (angiotensin
converting enzyme inhibitors, β-adrenoceptor blockers,
calcium channel antagonists) were minimal and well-tolerated
(Webb et al 1999; Kloner et al 2001; Vardi et al 2002). Comparable
results were obtained with newer phosphodiesterase 5
inhibitors vardenafil and tadalafil (Kloner et al 2003a, b; Pomara
et al 2004; Kloner et al 2004). A statistical evaluation of side-
effects of sildenfil after its approval did not demonstrate an
increased cardiovascular risk as compared with an adequate
reference population (Wysowski et al 2002). However, there
are a few, but important exceptions to mention: NO donors,
which have a marked blood pressure lowering effect, even if
most of them are not used as antihypertensive agents, and
α-adrenoceptor blocker, used as antihypertensives and in the
treatment of prostate hyperplasia. Patients treated with
phosphodiesterase 5 inhibitors must be informed about these
interactions.
Interaction of phosphodiesterase 5
inhibitor with antihypertensive
treatment
Nitric oxide donors
Looking at the mechanism of vasodilation induced by
phosphodiesterase 5 inhibitors, it becomes clear that the amount
of preactivation of the guanylate cyclase— NO system may
determine the degree of blood pressure lowering in response
to phosphodiesterase 5 inhibitors (Cheitlin et al 1999; Webb
et al 1999). Therefore, phosphodiesterase 5 inhibitors in
combination with any drug serving as a NO donor can lead to
life-threatening hypotension, as uncontrolled accumulation
of cGMP within the vascular smooth muscle cells can occur.
24 hours, equal to 6 half-lives of sildenafil, should elapse
between administration of a nitrate and sildenfil or vice-versa
(Cheitlin et al 1999). For vardenafil, with a similar half-life as
sildenafil, also 24 hours are required until nitrate oxide donors
can be used safely. For tadalafil, however, with a half-life of
17.5 hours, recent studies suggest that at least 48 hours should
elapse after the intake of 20 mg tadalafil before nitrates can be
administerd (Brock et al 2002; Corbin et al 2002; Emmick
et al 2002; Kloner 2002; Kloner et al 2002; Nichols et al
2002). If a patient, who has taken phosphodiesterase 5
inhibitors inadvertently receives nitrates and a marked drop
in blood pressure occurs, emergency measures may range from
Trendelenburg-position, aggressive fluid resuscitation to
intravenous application of adrenergic drugs, or even intra-aortic
balloon counterpulsation (Cheitlin et al 1999).
Table 3  Medical therapy, incidence of erectile dysfunction, and potential alternatives
Drug Potential alternative Comment
thiazide diuretics loop diuretics thiazide diuretics: higher
incidence of erectile
dysfunction than β-blockers
β-blockers angiotensin converting prognostic benefit after
enzyme inhibitors, myocardial infarction or in
angiotensin II receptor type-1 heart failure needs to be
blockers, calcium channel weighed against side effects
blockers
aldosterone receptor potassium sparing diuretics or limited information
antagonists eplerenone in the treatment of
(spironolactone) congestive heart failure
fibrates statins -
angiotensin-converting angiotensin II type-1 angiotensin II receptor
enzyme inhibitors receptor blockers type-1 blockers may even
improve sexual function
Notes: Some of the alternatives may not be applicable in individual patients
Compiled according to Langford et al. (1989), Carvajal et al. (1995), Llisterri et al. (2001), Ralph (2000), Rizvi et al. (2002), Schachter et al. (2000), and Bruckert et al. (1996).Vascular Health and Risk Management 2006:2(4) 453
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Alpha-adrenoceptor blockers
Another class of drugs used for treatment of hypertension
requires special attention: α-adrenoceptor blockers, such as
doxazosin and terazosin (used for both arterial hypertension
and benign prostatic hypertrophy) and tamsulosin (an α1a-
adrenoceptor blocker used in the treatment of prostatic
hyperplasia). When vardenafil was first released to the
market, it was contraindicated in combination with any α-
adrenoceptor blocker as significant hypotension had been
observed in some of the initial studies. This appeared also to
be the case for tadalafil in combination with non-selective
α1-adrenoceptor blockers (not for tamsulosin). Analysis of
subsequent studies, however, suggested that hypotension with
these combinations is less significant than initially assumed;
and therefore the label “precaution” is now officially used for
the combined use of PDE 5 inhibitors and α-adrenoceptor
blockers (Auerbach et al 2004; Kloner et al 2004).
As a rule of thumb, a baseline blood pressure of more
than 90/60 mmHg is a prerequisite for any PDE 5 inhibitor to
be administered. Furthermore, α-adrenoceptor blockers
should only be used in combination with PDE 5 inhibitors if
other alternatives do not appear to be applicable and only
under close medical monitoring.
Summary
In many forms of ED, cardiovascular risk factors, in particular
arterial hypertension, seem to be extremely common. While
causes for ED are related to a broad spectrum of diseases, a
generalized vascular process seems to be the underlying
mechanism in many patients, which frequently involves
endothelial dysfunction, ie, inadequate vasodilation in
response to endothelium-dependent stimuli, both in the
systemic vasculature and the penile arteries. Due to this close
association of cardiovascular disease and ED, patients with
ED should be evaluated for cardiovascular risk factors
including hypertension, cardiovascular disease or silent
myocardial ischemia. Cardiovascular patients, seeking
treatment of ED must be closely examined to determine
whether treatment of ED or sexual activity can be
recommended without significantly increased cardiac risk
according to the guidelines issued from the Princeton
Consensus Conference.
While consequent treatment of cardiovascular risk factors
should be accomplished in these patients, many
antihypertensive drugs may worsen sexual function as a drug
specific side-effect. Effective treatment for arterial
hypertension should not be discontinued as this, in the long
term, most likely deteriorates sexual function. Alternative
antihypertensive regimes should be administered with
individually tailored drug regimes with minimal side effects
on sexual function. Angiotensin II receptor type-1 blockers
may be associated with little side-effects or even with a slight
improvement of sexual function.
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